CSPC Innovation Pharmaceutical Co. Ltd. has refiled an application to list on the main board of the Hong Kong Stock Exchange, seeking fresh capital to sustain its transition from a food additive producer to an innovative drug developer. The company, previously known as Xin Nuo Wei, changed its stock name on June 17 and submitted the new prospectus on June 18 with CITIC Securities as sole sponsor. The move comes as the firm grapples with mounting research expenses and declining profitability in its core caffeine business, which has forced it to seek external funding to advance its pipeline of cancer-targeting therapies.

The shift in strategy has placed significant pressure on the company's financials. From 2023 to 2025, annual revenue fluctuated, coming in at 2.54 billion yuan, 1.98 billion yuan, and 2.16 billion yuan respectively. During this period, the bottom line swung from a profit of 126 million yuan in 2023 to losses of 304 million yuan and 634 million yuan in the subsequent years. This deterioration was driven by a sharp increase in R&D costs, which ballooned from 671 million yuan to 1.06 billion yuan over the three years, reaching 49.2% of total revenue in 2025.

The surge in R&D spending followed the 2024 acquisition of a controlling stake in Megalith Biopharmaceutical, the CSPC group's platform for antibody drugs, antibody-drug conjugates (ADCs), and mRNA vaccines. CSPC Innovation currently has more than 15 drug candidates in clinical or later stages of development. In January 2026, Megalith Biopharmaceutical, CSPC Pharmaceutical Group, and related entities entered a strategic collaboration with AstraZeneca, granting the multinational rights to develop and commercialize a portfolio of weight-management drugs outside Greater China. The deal includes potential milestone payments of up to $17.3 billion, with a $420 million upfront payment received in May 2026.

Despite the influx of capital from partnerships, the company's cash flow remains under strain. Cash and cash equivalents dropped from 3.77 billion yuan at the end of 2023 to 718 million yuan by the end of April 2026. Excluding the AstraZeneca upfront payment, current reserves would cover operations for only 17 months. Meanwhile, the parent company, CSPC Pharmaceutical Group Co. Ltd., faces its own headwinds, with revenue falling 10.4% in 2025 and net profit declining for a third consecutive year to 3.88 billion yuan, limiting its ability to fund group R&D initiatives.

Financial Performance (2023–2025)

Use of IPO Proceeds

CSPC Innovation plans to allocate approximately 60% of the listing proceeds to the clinical development of its core pipeline, specifically focusing on Phase Three trials for ADC candidates like SYS6010. Another 20% will be used to expand its commercialization team to around 180 employees covering 200 key hospitals in China. The remaining 15% is earmarked for acquiring complementary assets or technology platforms, targeting areas such as dual-target ADCs and mRNA delivery systems. The company hopes the listing will help it secure a valuation premium comparable to peers like RemeGen, which trades at a significantly higher price-to-book ratio in Hong Kong.